CompletedPhase 2NCT04522895
IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT
Studying Acute myelomonocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Heinrich-Heine University, Duesseldorf
- Principal Investigator
- Thomas Schroeder, PD Dr.University Hospital Duesseldorf Dept. of Hematology, Oncology and Clinical Immunology
- Intervention
- Enasidenib(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2024
Study locations (11)
- University Hospital Duesseldorf Dept. of Hematology, Oncology and Clinical Immunology, Düsseldorf, North Rhine-Westphalia, Germany
- Uniklinik RWTH Aachen Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation (Med. Klinik IV), Aachen, Germany
- Universitätsklinikum Köln Klinik I für Innere Medizin, Cologne, Germany
- Universitätsklinikum Carl Gustav Carus Medizinische Klinik und Poliklinik I, Dresden, Germany
- Universitätsklinikum Essen Klinik für Hämatologie und Stammzelltransplantation, Essen, Germany
- Universitätsklinikum Frankfurt Med. Klinik II, Frankfurt, Germany
- Universitätsklinikum Hamburg-Eppendorf Interdisziplinäre Klinik für Stammzelltransplantation, Hamburg, Germany
- Universitätsklinikum Heidelberg Innere Medizin V: Hämatologie, Onkologie und Rheumatologie, Heidelberg, Germany
- Universitätsklinikum Leipzig Medizinische Klinik und Poliklinik I, Hämatologie und Zelltherapie, Leipzig, Germany
- Klinikum rechts der Isar der TU München Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie, München, Germany
- Universitätsklinikum Münster Medizinische Klinik A / KMT Zentrum, Münster, Germany
Collaborators
Celgene Corporation · Koordinierungszentrum für Klinische Studien Düsseldorf
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04522895 on ClinicalTrials.govOther trials for Acute myelomonocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06994676A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid LeukemiasCrossbow Therapeutics, Inc.
- RECRUITINGPHASE2NCT06680661ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisLeland Metheny
- RECRUITINGPHASE2NCT06778187Oral-ATO for TP53-mutated Myeloid MalignanciesThe University of Hong Kong
- RECRUITINGPHASE1NCT06247787A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyChildren's Oncology Group
- RECRUITINGNCT06111612Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary InvolvementShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT05807932Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE1NCT05636514Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSClinical Hub for Interventional Research (CHOIR)
- RECRUITINGPHASE1, PHASE2NCT05092451Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesM.D. Anderson Cancer Center